SCHEMBL3017311

SCHEMBL3017311

Cc1ccccc1-c1csc(N2CCC(S(=O)(=O)c3cccc(Br)c3)CC2)n1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.42
NPC1 O15118 6/20 0.42
RAB9A P51151 6/20 0.42
AR P10275 3/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP1A2 P05177 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPN6 P29350 1/20 0.38
CDC25A P30304 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019194 0.93 AR (0.40) SMN1; SMN2NPC1RAB9AARMEN1
SCHEMBL3017299 0.91 AR (0.54) SMN1; SMN2NPC1RAB9AARMEN1
SCHEMBL2997894 0.90 RAB9A (0.43) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL3003584 0.89 SMN1; SMN2 (0.45) SMN1; SMN2NPC1RAB9AARMEN1
SCHEMBL3019012 0.89 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AARMAPK1
SCHEMBL3016323 0.89 RAB9A (0.47) SMN1; SMN2NPC1RAB9AARMEN1
SCHEMBL3017184 0.88 AR (0.46) SMN1; SMN2NPC1RAB9AARKMT2A
SCHEMBL3007689 0.86 RAB9A (0.40) SMN1; SMN2NPC1RAB9AARMEN1
SCHEMBL3012682 0.86 MEN1 (0.52) SMN1; SMN2NPC1RAB9AARMEN1
SCHEMBL3009743 0.86 RAF1 (0.50) SMN1; SMN2NPC1RAB9AARMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885NPC1 15/4885RAB9A 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.